Rhythm Pharmaceuticals (RYTM) is back in focus after positive interim results from a Phase 2 trial of setmelanotide in Prader Willi syndrome and encouraging ENDO 2026 data across several rare neuroendocrine obesity indications.

The latest clinical updates and analyst commentary come after a strong period for Rhythm Pharmaceuticals, with the share price at $110.41 and a 30-day share price return of 25.7%. Momentum has been building, reflected in a 90-day share price return of 28.0% and a 1-year total shareholder return of 65%. The 3-year total shareholder return is a very large multiple of the initial investment.

If progress in rare disease treatments has your attention, it may be worth seeing which other healthcare companies are gaining traction through AI driven approaches using our 39 healthcare AI stocks

With Rhythm Pharmaceuticals posting rapid share price gains and reporting revenue of $217.2 million alongside a loss of $207.8 million, investors now face a key question: is RYTM still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 20.8% Undervalued

With Rhythm Pharmaceuticals last closing at $110.41 against a narrative fair value of $139.47, the current price sits well below what the most followed model suggests, putting the recent trial updates and analyst revisions into sharper focus.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader-Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years.

Curious what underpins a higher fair value than today’s share price? The narrative leans on expectations for revenue expansion, a shift toward profitability, and a future earnings multiple often associated with mature, high growth franchises.

Result: Fair Value of $139.47 (UNDERVALUED)

However, Rhythm Pharmaceuticals still faces meaningful risks, including continued operating losses with high R&D spend and heavy reliance on setmelanotide as its core revenue driver.

Another View: Rhythm Pharmaceuticals Looks Expensive On Sales

That 20.8% undervaluation signal sits awkwardly next to Rhythm Pharmaceuticals' current P/S ratio of 34.8x, compared with 9.6x for peers and 12.4x for the wider US Biotechs industry, and a fair ratio of 20.9x, which suggests the market could shift closer to that lower level over time. Is the optimism baked into today’s price too rich for the risks involved?

Next Steps

Questions about whether the upbeat tone around Rhythm Pharmaceuticals truly reflects the balance of risks and rewards are fair. Move quickly and test that sentiment against the underlying data using the 3 key rewards.

Looking for more investment ideas beyond Rhythm Pharmaceuticals?

If Rhythm Pharmaceuticals has sharpened your focus, now is a good moment to broaden your watchlist and uncover other opportunities that fit different parts of your portfolio.

• Target potential value opportunities by checking companies that currently screen as 41 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks highlighted as 8 dividend fortresses.
• Prioritise resilience by scanning companies identified in the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.